Regulatory Pathway for Achaogen Looks Better; Is It Aimed At Viable Commercial Market?
This article was originally published in RPM Report
Executive Summary
With the FDA bottleneck for new anti-infectives showing signs of improvement, the next concern is whether providers will pay high premiums for new anti-infectives and the related challenge of finding the right patients to make high-cost treatments make sense.
You may also be interested in...
Paying for New Drugs for New Bugs: Regulation is Only One Side of the Coin
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN
FDA is sending a message to industry and Congress of its ongoing work to help companies with antibiotic drug development– beyond the requirements of the FDA Safety and Innovation Act.